Derrick Lane, MD
Family Medicine · Macon, GANPI 1124079447
Payments from drug & device makers
Across 129 payments — averaging $32.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Hartmann USA, Inc.$1K
- AbbVie$421
- Kerecis Limited$361
- AstraZeneca$211
- Smith+Nephew$190
- Mimedx Group, Inc.$159
- plus $2K from 35 others
What the payments were for
- Consulting fees$1,25030%
- Food & beverage$2,91070%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Hartmann USA, Inc. | 2 | $1,263 |
| AbbVie(2 entities) | 20 | $421 |
| Kerecis Limited | 9 | $361 |
| AstraZeneca | 11 | $211 |
| Smith+Nephew | 9 | $190 |
| Mimedx Group, Inc. | 2 | $159 |
| Lilly USA, LLC | 9 | $158 |
| Organogenesis Inc. | 5 | $157 |
| Reapplix Inc. | 2 | $150 |
| Boehringer Ingelheim | 6 | $130 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $73 |
| Exact Sciences | 4 | $68 |
| Mylan Specialty L.p. | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Reprise Biomedical, Inc. | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Convatec Inc. | 2 | $34 |
| Gilead | 2 | $30 |
| Novo Nordisk | 1 | $27 |
| Abbott | 1 | $22 |
| Merck | 1 | $22 |
| Amgen | 1 | $21 |
| Vertex | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Lifenet Health | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Solventum Corporation | 1 | $17 |
| Hydrofera LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Molnlycke Health Care US, LLC | 1 | $13 |
| Advanced Oxygen Therapy Inc. | 1 | $13 |
| Reddress USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,160 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tobramycin Sulfate | 40 | $76,392 |
| EliquisApixaban | 55 | $23,298 |
| JardianceEmpagliflozin | 40 | $20,677 |
| TrulicityDulaglutide | 14 | $19,361 |
| MounjaroTirzepatide | 13 | $17,636 |
| JanuviaSitagliptin Phosphate | 15 | $16,421 |
| FarxigaDapagliflozin Propanediol | 20 | $13,924 |
| LinzessLinaclotide | 18 | $11,443 |
| MyrbetriqMirabegron | 17 | $8,425 |
| GemtesaVibegron | 16 | $7,576 |
| InvokanaCanagliflozin | 25 | $7,292 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $5,011 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,809 |
| MovantikNaloxegol Oxalate | 14 | $3,087 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $36,99727 claims |
| PfizerEliquis | $19 | $23,29855 claims |
| Boehringer IngelheimJardiance | $130 | $20,67740 claims |
| MerckJanuvia | $22 | $16,42115 claims |
| AbbVieLinzess, Combigan | $421 | $14,11331 claims |
| AstraZenecaFarxiga | $211 | $13,92420 claims |
| Astellas Pharma US IncMyrbetriq | $37 | $8,42517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Macon
- Frederick BurtonMacon$66K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.